BR112012019619A2 - uso de pentoxifilina para evitar ou tratar a constipação - Google Patents

uso de pentoxifilina para evitar ou tratar a constipação

Info

Publication number
BR112012019619A2
BR112012019619A2 BR112012019619A BR112012019619A BR112012019619A2 BR 112012019619 A2 BR112012019619 A2 BR 112012019619A2 BR 112012019619 A BR112012019619 A BR 112012019619A BR 112012019619 A BR112012019619 A BR 112012019619A BR 112012019619 A2 BR112012019619 A2 BR 112012019619A2
Authority
BR
Brazil
Prior art keywords
pentoxifylline
prevent
treat constipation
constipation
treat
Prior art date
Application number
BR112012019619A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhiquan Zhao
Original Assignee
Lunan Better Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Better Pharmaceutical Co Ltd filed Critical Lunan Better Pharmaceutical Co Ltd
Publication of BR112012019619A2 publication Critical patent/BR112012019619A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012019619A 2010-02-09 2010-12-03 uso de pentoxifilina para evitar ou tratar a constipação BR112012019619A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010101237779A CN102145004B (zh) 2010-02-09 2010-02-09 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途
PCT/CN2010/001954 WO2011097788A1 (zh) 2010-02-09 2010-12-03 己酮可可碱在预防或治疗便秘中的用途

Publications (1)

Publication Number Publication Date
BR112012019619A2 true BR112012019619A2 (pt) 2016-05-03

Family

ID=44367139

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019619A BR112012019619A2 (pt) 2010-02-09 2010-12-03 uso de pentoxifilina para evitar ou tratar a constipação

Country Status (5)

Country Link
JP (1) JP5575927B2 (zh)
CN (1) CN102145004B (zh)
AU (1) AU2010345621B2 (zh)
BR (1) BR112012019619A2 (zh)
WO (1) WO2011097788A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356630B (zh) * 2012-03-31 2016-08-03 鲁南制药集团股份有限公司 含有己酮可可碱和普卡必利的药物组合物及其医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143726A0 (en) * 1998-12-14 2002-04-21 Cellegy Pharma Inc A pharmaceutical composition containing a nitric oxide donor
IL154202A0 (en) * 2000-07-31 2003-07-31 Cellegy Pharma Inc Pharmaceutical compositions for treating anorectal disorders
CN101239050A (zh) * 2008-03-14 2008-08-13 沈阳双鼎制药有限公司 一种己酮可可碱缓释片及其制备方法

Also Published As

Publication number Publication date
AU2010345621B2 (en) 2014-01-23
CN102145004B (zh) 2012-03-21
WO2011097788A1 (zh) 2011-08-18
AU2010345621A1 (en) 2012-09-13
JP5575927B2 (ja) 2014-08-20
CN102145004A (zh) 2011-08-10
JP2013518915A (ja) 2013-05-23

Similar Documents

Publication Publication Date Title
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
CL2014003017A1 (es) Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CL2015000640A1 (es) Variantes de hppd y métodos de uso
BR112013002279A2 (pt) ensaios de biomacador para detectar ou medir inibição de atividade de tor quinase
BR112013025353A2 (pt) combinações de compostos de inibidores de akt e erlotinibe e métodos de uso
BR112013016030A2 (pt) compostos e seu uso como inibidores de bace
AP3849A (en) Use of inhibitors of the activity or function of pi3k
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
BR112013008528A2 (pt) métodos para tratar psoríase
FI20105639A0 (fi) Mikroselluloosan valmistus
CO6781486A2 (es) Compuestos y su uso
BR112013012452A2 (pt) uso de dispersões aquosas como primers
BR112013032360A2 (pt) compostos inibidores de glioblastoma e seu uso
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
BR302013000698S1 (pt) Configuração aplicada em dispensador de água com filtro
BR112013023968A2 (pt) uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune
BRDI7106339S (pt) Configuração aplicada em bico para mamadeira
BRPI0822264A2 (pt) Dapsona para tratar rosácea
BRPI1013788A8 (pt) uso de monocloroupéia para tratar águas industriais.
ES2609459T8 (es) Compuestos heterocíclicos condensados y su uso
IT1403375B1 (it) Microcontrollore multiprocessore espandibile/parametrizzato
BR112013009743A2 (pt) uso de deposito de fosfolipidio viscoso estavel ao armazenamento para tratar ferimentos
BR112012019619A2 (pt) uso de pentoxifilina para evitar ou tratar a constipação

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)